Evaluation Kanitinib Treatment of Recurrent or Metastatic Malignant Solid Tumors Safety, Tolerability and Pharmacokinetic Open, Dose Escalation Phase I Clinical Study

Trial Profile

Evaluation Kanitinib Treatment of Recurrent or Metastatic Malignant Solid Tumors Safety, Tolerability and Pharmacokinetic Open, Dose Escalation Phase I Clinical Study

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs Kanitinib (Primary)
  • Indications Gastric cancer; Liver cancer; Lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Thyroid cancer
  • Focus Adverse reactions
  • Sponsors KONRUNS Pharmaceutical
  • Most Recent Events

    • 04 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top